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Background: Interferon beta (IFNb) was the first proven drug for the treatment 
of multiple sclerosis (MS). The diagnosis of MS frequently occurs in women at child-
bearing age (especially in twenties and thirties). Therefore, the pregnancy process 
is major concern for many women with MS. Data on women exposed to IFNb 
during pregnancy are limited. The aim of our study was to investigate the terato-
genic potential of IFNb on embryonic development via embryo culture technique. 
Recently, this technique has been often used for determining teratogenic effect of 
pharmacologic drugs and potential teratogens on embryonic development.
Materials and methods: In this study, IFNb was applied to the culture medium 
and after 48 h of culture effects of IFNbs (1000 IU/IFNb-1a and 1000 IU/IFNb-1b) 
on embryonic development were morphologically investigated.
Results: According to morphologic scoring system, total morphologic score, so-
mite number and protein contents were similar between control group and two 
experimental groups (p > 0.05). On the other hand, yolk sac diameter, crown-
-rump length and head length were significantly decreased in two experimental 
groups compared with control group (p < 0.05).
Conclusions: Consequently, IFNb-1a and IFNb-1b, applied to the culture medium, 
have no macroscopic teratogenic effect on embryonic development. However, in 
respect of morphometric measurements, IFNb-1a and IFNb-1b have caused growth 
retardation in embryo. This research related to interferon was the first study using 
vitro embryo culture technique; thus, in our point of view, future studies which 
will be performed by using different doses of IFN will contribute to the literature. 
(Folia Morphol 2016; 75, 2: 257–263)
Key words: interferon b-1a, interferon b-1b, whole rat embryo culture
INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating, 
inflammatory, neurodegenerative and neuroimmune 
disorder that affects white matter of central nervous 
system [16]. MS is the most common neurologic 
disease among young adults, typically starting in the 
third and fourth decades of life. Women are more 
frequently affected than men [6, 46]. Recent epide-
miological studies have demonstrated that the ratio 
of female/male is gradually increasing worldwide. 
Thus, MS especially affects women at childbearing 
age [13, 35, 37]. The status of the embryo affected 
by the disease, the manner of drug treatment and un-
certainties regarding the mechanisms of drug action 
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in the process of childbirth and breastfeeding made 
the pregnant women with MS anxious. Pregnancy 
has no adverse effects on the course of MS [9, 34, 
44]. According to the current literature, it has not 
been determined whether an increase in miscarriage, 
stillbirth, malformations and birth complications is 
related to MS [34, 39]. 
Interferon beta-1b (IFNb-1b, Betaferon/Betaseron) 
was the first drug approved for the treatment of MS 
by Food and Drug Administration (FDA) in 1993 [21, 
22, 43]. Later, interferon beta-1a (IFNb-1a, Avonex/Re-
bif) was approved for the treatment of Relapsing-Re-
mitting Multiple Scleros. IFNb also received approval 
to treat Secondary Progressive Multiple Sclerosis in 
some countries [25]. Interferon (IFN) was discovered 
accidentally by Alick Isaacs and Jean Lindenmann in 
1957 [20]. IFNs are located within the family of glyco-
proteins known as cytokines. They are water-soluble 
and endogenous substances, with molecular weight 
of 17–25 kilodaltons (kDa). IFNs are produced natural-
ly by the several cells such as erythrocytes, fibroblasts, 
epithelial cells and natural killer cells, in response to 
bacteria, viruses, parasites and tumour cells. IFNs have 
a very wide antiviral spectrum [24].
A vast number of different IFN molecules were 
detected in human cells. IFNs were classified among 
three classes: type I IFN, type II IFN, and type III IFN. 
The mammalian type I IFNs are designated IFN-a 
(alpha), IFN-b (beta), IFN-k (kappa), IFN-d (delta), 
IFN-e (epsilon), IFN-t (tau), IFN-o (omega), and IFN-z 
(zeta, also known as limitin) [15]. A mature IFNb pro-
tein was composed of 145 amino acids [5]. IFNb has 
two subtypes namely IFNb-1a and IFNb-1b. Recently, 
both interferons have a common use in clinics [10]. 
IFNs were reported to have antiviral, antiproliferative, 
immunomodulatory and anti-apoptotic activity [21]. 
Besides, they have effects on the regulation of cell 
growth and differentiation [41]. 
Experimental and clinical studies have revealed 
that IFNb decreased the progression of MS by re-
ducing relapse rate, frequency and inflammatory 
indicators on magnetic resonance imaging (MRI) [27]. 
However, the mechanism of IFNb action in the treat-
ment of MS has not been elucidated yet [26]. Recently, 
studies have focused on the immunomodulatory and 
antiproliferative effects of IFNb [41]. For the women 
at childbearing age with MS, it is important to decide 
to have a planned pregnancy. Otherwise, they will 
continue to use their medications during pregnancy 
which may negatively affect the health of the embryo. 
In terms of a planned pregnancy, the physicians rec-
ommend to quit the prescribed medication 3 months 
before conception [8, 12].
Several studies showed that using IFNb during 
the first 3 months of pregnancy increased the risk of 
stillbirth and low birth weight [2, 4]. However, there 
are limited studies investigating their teratogenic 
effects during pregnancy, thus IFNb-1a, IFNb-1b have 
received category C by FDA [12].
The in vitro culture technique was described by 
New and Stein in 1964 [in 42]. Recently, this method 
has been commonly used to determine the effects of 
pharmacological agents, hormones, chemical and 
physical factors on the embryonic development and 
to determine potential teratogens [30]. The in vitro 
culture of post-implantation rat embryos during the 
early organogenesis period (from 9.5 to 11.5 preg-
nancy days) makes it possible to determine risk of 
teratogenicity in homologous serum [11]. The present 
study was performed to clarify the in vitro effects 
of IFNb-1a and IFNb-1b on embryonic development 
during the organogenesis period in the rat.
MATERIALS AND METHODS
This study was approved by the Experimental Ani-
mals Ethics Committee of Erciyes University, Turkey (The 
Ethics Committee Number: 12/101). Wistar rats were 
used and obtained from the Clinical and Experimental 
Research Centre, Medical Faculty of Erciyes University. 
The female rats (approximately 8 weeks of age and 
weighing 150–250 g) were kept in cages as three 
groups. The males of the same strain were housed 
singly in mating cages. Male and female rats were 
placed together in the evening (one pair per cage), and 
the presence of a vaginal plug the following morning 
was taken to indicate mating had occurred.
On the assumption that mating occurred around 
mid-night, the female was considered to be 0.5 day 
pregnant at noon in the following day. The pregnant 
rats were sacrificed by overdose ether at 9.5 days 
of gestation, between 9 a.m. and 10 a.m. in the 
morning and the embryos were removed from the 
mother by the procedure described by New [28]. We 
used 3 dams for each group (totally 9 dams). Using 
a dissection microscope, the decidual mass was split 
to expose the conceptus, which was gently teased free 
and immediately immersed in Hank’s balanced salt 
solution. The damaged and underdeveloped embryos 
were discarded. There were 4 to 5 embryos in each 
bottle which contained 1 mL of immediately centri-
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fuged, heat inactivated whole rat serum (WRS) per 
embryo and these embryos were randomised from 
several rats.
In order to assess the effect of the IFNb-1a (Avonex) 
and IFNb-1b (Betaferon) on total embryonic growth, 
embryos were divided into three groups (10 embryos 
in control group and 9 embryos per two experimental 
groups). The control group embryos were cultured 
in WRS. The administration dosages of IFNb-1a and 
IFNb-1b were determined according to the data from 
previous cell culture studies [47]. For the experimental 
groups, 1000 IU IFNb-1a and 1000 IU IFNb-1b were 
added to WRS. After 48 h culture period, the embryos 
from each group were examined under the dissecting 
microscope and assessed according to the morpho-
logical scoring system which takes account of the 
growth and differentiation of different embryological 
features, including the appearance of yolk sac circula-
tion, allantois, body flexion, heart, caudal neural tube, 
hindbrain, midbrain, forebrain, otic system, optic 
system, olfactory system, branchial arches (bars), 
maxillary processes, mandibular processes, forelimbs, 
hindlimbs and somite number [29]. Mean yolk sac 
diameter, crown-rump length and head lengths were 
also measured by using ImageJ program (http://rsb.
info.nih.gov/ij/docs/index.html). Additionally, protein 
contents of embryos were determined with using 
Folin Phenol reagents for all groups [11].
Statistical analysis
Data of the morphological score and somite num-
ber, yolk sac diameter, crown-rump length and head 
length were statistically analysed. All data sets were 
subjected to normality test by the Shapiro-Wilk test. 
Comparison between the groups was performed by 
the one way analysis of variance (ANOVA; multiple 
comparisons were carried out with Tukey Test). Statis-
tical significance was set at p < 0.05. All analyses were 
performed with the statistical package for scientist 
(SIGMASTAT) Windows version 3.10.
RESULTS 
The results of the present study revealed the 
development of the control group embryos were 
normal and morphological scoring results were close 
to the development of an 11.5-day in vivo embryo 
(Fig. 1). The embryos cultured in IFNb-1a and IFNb-1b 
showed that there was no significant difference 
in total morphological score, somite number and 
embryo protein content compared with embryos 
grown only in WRS (p > 0.05) (Fig. 1). However, 
when compared with control group, a significant 
retardation in yolk sac diameter, crown rump length 
and head length parameters in two experimental 
groups was determined (p < 0.05). Related results 
are given in Table 1.
Parameters related to the nervous system were 
also considered (Table 2). In the experimental groups, 
the number of embryos that had growth retardation 
in parameters related to nervous system (caudal neu-
ral tube, hindbrain, midbrain, forebrain and olfac-
tory system) were larger compared with the control 
group. This numerical excess was not statistically 
significant; however, most of the embryos exposed 
to IFNb-1a and IFNb-1b had open posterior neural 
tubes, anterior neuoropores and poor neural system 
development (Fig. 1).
DISCUSSION
Various disease-modifying drugs, including IFNb-1a 
and IFNb-1b, glatiramer acetate, natalizumab, mitox-
antrone, and fingolimod that are licensed worldwide 
to reduce the frequency of clinical attacks with the 
expectation of slowing disability progression [14]. 
Figure 1. Rat embryos outside of the yolk sac at 11.5 days of 
gestation following 48-h culture period in whole rat serum (control 
group) (A, B) and whole rat serum +1000 IU/mL interferon beta-1a 
(C, D); f — forebrain; m — midbrain, h — hindbrain; o — optic 
vesicle; ot — otic vesicle; he — heart; s — somite; oan — open 
anterior neuropore, can — closed anterior neuropore.
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Great majority of studies related to IFNs have been 
directed towards to determination of their effects 
on diseases and biological structures [9, 39]. At pres-
ent, recommendation to quit the use of IFNb during 
pregnancy is based on findings from animal studies; 
in primates, administration of up to 100 times the 
recommended weekly human dose of IFNb (based 
upon a body surface area comparison) was not asso-
ciated with teratogenicity or adverse effects on foetal 
development [18]. In spite of these data, the FDA 
has given IFNb drugs a pregnancy category C rating, 
based on experimental primate studies showing abor-
tifacient activity at 2–100 times the corresponding 
human dose [12].
By virtue of the first trimester of pregnancy is 
characterised by precisely choreographed gene ex-
pression and rapid cell division that lays the founda-
tion for later foetal growth and development [7], it is 
completely possible that early IFN exposure may have 
affect these early processes to cause later prematurity 
and decreased growth.
To the best of our knowledge, there is no embryo 
culture study to investigate the teratogenic effects of 
IFNb-1a and IFNb-1b on embryos.
Table 1. In vitro embryonic development in control and interferon beta (IFNb) groups
Control group 1000 IU/mL IFNb-1a 1000 IU/mL IFNb-1b
Mean ± SD Min Max Mean ± SD Min Max P Mean ± SD Min Max P
Total  
morphological 
score
56.25±3.04 51 60 56.17 ± 1.32 54 58 0.997 53.56 ± 2.46 49 57 0.57
Somite  
number
22.2 ± 2.45 19 25 21.88 ± 1.13 20 23 0.833 21.66 ± 0.86 21 23 0.902
Yolk sac  
diameter 
[mm]
4.79 ± 0.37 4.26 5.58 4.08 ± 0.32 3.59 4.43 000** 4.12 ± 0.32 3.49 4.54 001*
Crown-rump 
length [mm]
3.78 ± 0.43 3.07 4.35 3.34 ± 0.10 3.21 3.57 008* 3.29 ± 0.19 3.02 3.58 003*
Head length 
[mm]
1.59 ± 0.10 1.46 1.74 1.44 ± 0.03 1.40 1.50 000** 1.47 ± 0.04 1.40 1.55 002*
Embryo  
protein  
content [mg]
187.27 ± 45.77 136.77 242.83 182.68 ± 7.09 168.45 194.62 0.935 184.83 ± 13.43 161.57 201.51 0.981
*One Way Analysis of Variance (ANOVA) was applied; p < 0.05; SD — standard deviation
Table 2. The morphological score of brain parameters (caudal neural tube, hindbrain, midbrain, forebrain, olfactory system) in control 
group, 1000 IU/mL IFNb-1a and 1000 IU/mL IFNb-1b groups
N Caudal neural tube Hindbrain Midbrain Forebrain Olfactory  
system
Morphological 
score
0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3
Control group 10 5 5 1 4 5 1 5 4 6 4 4 6
1000 IU/mL 
IFNb-1a
9 7 2 2 7 9 1 7 1 2 7
1000 IU/mL 
IFNb-1b
9 9 3 6 3 6 3 6 9
N — the number of embryo; Caudal neural tube — 0: Neural layer or neural folds created, 1: Neural layer closed but uncombined with neural fold, 2: Neural folds combined at 4–5 somites 
level, 3: Posterior neuropore is shaped but open, 4: A small aperture in the posterior neuropore, 5: Posterior neuropore is closed; Hindbrain — 0: Neural layer was formed, 1: Neural fold is 
V-shaped, 2: Neural fold is U-shaped, 3: Anterior neuropore is formed but open, 4: Anterior neuropore is closed, rhombencephalon is shaped, 5: Upper edge of the fourth ventricle and  
pons inosculated; Midbrain — 0: Mesencephalic brain folds or neural layer formed, 1: Neural fold is V-shaped, 2: Neural fold is U-shaped, 3: Mesencephalic fold partially merged,  
4: Mesencephalon is merged, 5: A chamber is formed between the rhinencephalon and the mesencephalon; Forebrain — 0: Neural layer is formed, 1: Neural fold is V-shaped, 2: Neural 
fold is U-shaped, 3: Prosencephalic fold partially merged, 4: Prosencephalon is merged, 5: Telencephalic evagination formed; Olfactory system — 0: No symptoms, 1: Olfactory layer is 
formed, 2: Olfactory layer is surrounded, 3: Olfactory protrusion is obvious
261
İ. Uçar et al., Effect of interferon on embryonic development
In this study, in order to determine the level of de-
velopment of cultured embryos, total morphological 
scoring method was used [23]. When developments 
of embryos were evaluated, no significant differences 
were detected among the control and experimental 
groups. On the other hand, when yolk sac diameter, 
crown rump length and head length were evaluat-
ed, significant differences were determined among 
the control and experimental groups. In the current 
literature, the yolk sac diameters of control embryos 
(11.5 days of age) were reported as 3.17 ± 0.14 mm 
[31], 5.0 ± 0 mm [42], 5.70 ± 0.38 mm, respectively 
[45]. In this study, yolk sac diameter was calculated as 
4.79 ± 0.37 mm in control group and 4.08 ± 0.32 mm, 
4.12 ± 0.32 mm in experimental IFNb-1a and 
IFNb-1b groups, respectively. In the current literature, 
the value of crown-rump lengths were reported to 
range between 2.80 ± 0.11 and 5.4 ± 0.18 mm in 
embryos of control groups (11.5 days of age) [31, 42, 
45]. In our study, the average crown-rump lengths 
were determined in the control group as 3.78 ± 
± 0.43 mm, and 3.34 ± 0.10 mm, 3.29 ± 0.19 mm in 
experimental IFNb-1a and IFNb-1b groups, respectively. 
In another study, mean head length of embryos in the 
control group was reported as 2.0 mm [36], while in 
our study, head lengths of the embryos were meas-
ured as 1.59 ± 0.10 mm in the control group, 1.44 ± 
± 0.03 mm and 1.47 ± 0.04 mm in experimental 
IFNb-1a and IFNb-1b groups, respectively. As there 
was no study to use IFN in embryo culture currently, 
we cannot compare our experimental results. Thus, 
in our opinion, the decreased results in experimental 
groups may be the result of IFN use, while the dis-
crepancy of the results of control group may be due 
to diversity of working environment, the researchers 
and rat species.
Studies in humans, Amato et al. [2] demonstrated 
that IFNb use during pregnancy did not increase the 
risk of spontaneous miscarriage; however, it was 
related to low birth weight and short birth length. 
Boskovic et al. [4] showed that the usage of IFNb in 
the first 3 months of pregnancy caused foetal loss and 
low birth weight when compared to healthy pregnant 
control group and unexposed pregnant women with 
MS. On the contrary, Hellwig et al. [17] stated that 
congenital anomalies were in the normal rate in preg-
nant women used IFNb and concluded the drug not 
to have any teratogenic risk. Sandberg-Wollhem et al. 
[40] investigated the teratogenic effects of IFNb-1a on 
425 MS patients treated with IFNb-1a in the process 
of pregnancy by injection under the skin for at least 
45 days. They determined 49 spontaneous abortions, 
4 stillbirth and 4 children with congenital anomalies; 
the incidence of spontaneous abortion and congenital 
anomalies have been noted within normal range.
In this study, the similarities between the results 
related to the total morphological score and somites 
number in all groups demonstrated that mentioned 
doses of IFNb-1a and IFNb-1b had no teratogen-
ic effect on the embryos. Considering this aspect; 
our results were consistent with Hellwig et al. [17]. 
However, the significant differences between the 
control and experimental groups in terms of yolk sac 
diameter, crown-rump length and head length param-
eters revealed that embryos growing in IFNb-1a and 
IFNb-1b added medium had lower body size. When 
evaluated in this respect, our results were consistent 
with previous studies investigating the relationship 
between the use of IFNb and its teratogenicity dur-
ing pregnancy [2, 4]. They determined that using 
IFNb during the first 3 months of pregnancy caused 
low birth weight and short stature compared to the 
healthy control group.
In the treatment of MS, the effects of IFNb-1a and 
IFNb-1b on developing embryos during pregnancy are 
unclear and also being a disease involving the nervous 
system; in our opinion these drugs can potentially 
affect the nervous system of embryos, in case of use 
during pregnancy. IFNs are naturally produced inhib-
itors of cell growth that can also affect differentiated 
cell function [38]. IFNs have been previously shown 
to inhibit the hormone-induced synthesis of several 
enzymes [3, 19, 32] and the differentiation and pro-
liferation of glial cells [1, 33]. Researchers investigated 
the effect of IFN-alpha/beta on the expression of 
glycerol phosphate dehydrogenase (GPDH) in both C6 
glioma cells and pure cultures of oligodendrocytes. 
GPDH is a biochemical marker for oligodendrocytes 
and is known to be developmentally regulated and 
steroid inducible. A pre-treatment of these cells with 
75 U/mL of IFN-alpha/beta resulted in an inhibition 
of the hydrocortisone induction of GPDH enzymatic 
activity by 50% and 40% in C6 cells and oligodendro-
cytes, respectively. They also found that IFN impaired 
the accumulation of GPDH mRNA in both cell types. 
These results demonstrate that IFNs are capable of 
modifying the cellular response to hormones in cells 
of neuroepithelial origin, and suggest the possibility 
that IFNs may be able to influence the development 
and function of the brain [33]. Thus, embryos cultured 
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in medium with IFNb-1a and IFNb-1b were evaluated 
in terms of development of the nervous system. We 
determined numerical redundancy in the embryos 
of the experimental groups pointing out retardation 
in the nervous system. Therefore, in our opinion, 
IFNb-1a and IFNb-1b may affect the development of 
the neural system. The redundancy in the number of 
the embryos that have poorer neural system develop-
ment in the experimental groups may be considered 
in later studies. 
Limitations of the study
Our study had some limitations that make it difficult 
to generalise the results for all of the conditions. The 
first limitation of our study was the dose of IFNb; the 
effect of different doses of IFNb on embryo development 
was not investigated in this study. The second limitation 
was the assessment criteria. We didn’t use histological 
examination; we evaluated embryonic development by 
using morphologic score, protein content and morpho-
metric measurements. 
CONCLUSIONS
Together with a wide range of other in vitro studies 
dealing with the teratogenicity of several different 
molecules, the present findings suggest that the rat 
post-implantation embryo culture system is a very use-
ful method for teratological studies and also particu-
larly suitable for the assessment of specific effects on 
morphogenetic events occurring during early organo-
genesis in mammalian embryos. Consequently, our 
study demonstrated that 1000 IU/mL IFNb-1a and 
1000 IU/mL IFNb-1b did not have macroscopic terato-
genic effects on the growth of embryos. However, low-
er values in yolk sac diameter, crown-rump length and 
head length parameters showed that indicated doses 
of IFNb-1a and IFNb-1b caused growth retardation. As 
this is the first study using IFNb in vitro embryo culture 
technique, the future studies planned with different 
doses of IFNb and effects of IFNb using at different 
stages of pregnancy will contribute to the literature. 
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